Kininogen domain 3 contains regions recognized by antiphosphatidylethanolamine antibodies

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 1, 2003, Pages 132-138

  Katsunuma, J ^a   Sugi, T ^a   Inomo, A ^a   Matsubayashi, H ^a   Izumi, S I ^a   Makino, T ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiphosphatidylethanolamine antibodies; Antiphospholipid antibodies; Kininogen; Recurrent pregnancy loss; Thrombosis

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G; KININOGEN; PEPTIDE;

ADULT; AMINO ACID SEQUENCE; ARTICLE; BINDING COMPETITION; BINDING SITE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PREGNANCY; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; RECURRENT ABORTION; SYNTHESIS;

ABORTION, HABITUAL; ADULT; AMINO ACID SEQUENCE; BINDING SITES; BINDING, COMPETITIVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN G; KININOGENS; MOLECULAR SEQUENCE DATA; PEPTIDES; PREGNANCY; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

EID: 0141595881     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00022.x     Document Type: Article

References (52)

1. Staub HL, Harris EN, Khamashta MH, Savidge G, Chahade WH, Hughes GRV. Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis. Ann Rheumatol Dis 1989; 48: 166-9.
2. Karmochkine M, Cacoub P, Piette JC, Godeau P, Boffa MC. Antiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematosus with thrombosis. Clin Exp Rheumatol 1992; 10: 603-5.
3. Karmochkine M, Berard M, Piette JC, et al. Antiphosphatidylethanolamine antibodies in systemic lupus erythematosus. Lupus 1993; 2: 157.
4. Boffa MC, Berard M, Sugi T, McIntyre JA. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies detected by ELISA. II. Kininogen reactivity. J Rheumatol 1996; 23: 1375-9.
5. Berard M, Sugi T, McIntyre JA, Chantome R, Marcelli A, Boffa MC. Prevalence and kininogen-dependence of antiphosphatidylethanolamine antibodies. Nouv Rev Fr Hematol 1995; 37 (Suppl. II): S69-72.
6. Sugi T, Katsunuma J, Izumi S, McIntyre JA, Makino T. Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses. Fertil Steril 1999; 71: 1060-5.
7. Gris JC, Quere I, Sanmarco M, et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmunewomen with unexplained recurrent primary early foetal loss. Thromb Haemost 2000; 84: 228-36.
8. McIntyre JA, Wagenknecht DR. Anti-phosphatidylethanolamine (aPE) antibodies: a survey. J Autoimmun 2000; 15: 185-93.
9. Sanmarco M, Alessi MC, Harle JR, et al. Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses. Thromb Haemost 2001; 85: 800-5.
10. Balada E, Ordi-Ros J, Paredes F, Villarreal J, Mauri M, Vilardell-Tarres M. Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. Scand J Rheumatol 2001; 30: 235-41.
11. Sugi T, McIntyre JA. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 1995; 86: 3083-9.
12. Sugi T, McIntyre JA. Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies. Thromb Haemost 1996; 76: 354-60.
13. Griffin JH. Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc Natl Acad Sci USA 1978; 75: 1998-2002.
14. Silverberg M, Dunn JT, Garen L, Kaplan AP. Autoactivation of human Hageman factor: Demonstration utilizing a synthetic substrate. J Biol Chem 1980; 255: 7281-6.
15. Tankersley DL, Finlayson JS. Kinetics of activation and autoactivation of human factor XII. Biochemistry 1984; 23: 273-9.
16. Kaplan AP, Joseph K, Shibayama Y, Reddigari S, Ghebrehiwet B, Silverberg M. The intrinsic coagulation/kinin-forming cascade: Assembly in plasma and cell surfaces in inflammation. Adv Immunol 1997; 66: 225-72.
17. Schmaier AH, Kuo A, LundbergD, Murray S, Cines DB. The expression of high molecular weight kininogen on human umbilical vein endothelial cells. J Biol Chem 1988; 263: 16327-33.
18. Van Iwaarden F, deGroot PG, Bouma BN. The binding of high molecular weight kininogen to cultured human endothelial cells. J Biol Chem 1988; 263: 4698-703.
19. Reddigari SR, Kuna P, Miragliotta GF, Shibayama T, Nishikawa K, Kaplan AP. Human high molecular weight kininogen binds to human umbilical vein endothelial cells via its heavy and light chains. Blood 1993; 81: 1306-11.
20. Hassan AAK, Cines DB, Herwald H, Schmaier AH, Muller Esterl W. Mapping the cell binding site on high molecular weight kininogen domain 5. J Biol Chem 1995; 270: 19256-61.
21. Reddigari SR, Shibayama T, Brunnee T, Kaplan AP. Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J Biol Chem 1993; 268: 11982-7.
22. Colman RW, Bagdasarian A, Talamo RC, et al. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor dependent pathways. J Clin Invest 1975; 56: 1650-62.
23. Wuepper KD, Miller DR, Lacombe MJ. Flaujeac trait. Deficiency of human plasma kininogen. J Clin Invest 1975; 56: 1663-72.
24. Saito H, Ratnoff OD, Waldmann R, Abraham JP. Fitzgerald trait: deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface mediated reactions of clotting, fibrinolysis, generation of kinins, and the property of diluted plasma enhancing vascular permeability (PF/DIL). J Clin Invest 1975; 55: 1082.
25. Halbmayer WM, Haushofer A, Schon A, et al. The prevalence of moderate and severe factor XII (Hageman factor) deficiency among the normal population. Evaluation incidence factor XII deficiency among 300 healthy blood donors. Thromb Haemost 1994; 71: 68-72.
26. Lammle B, Wuillemin WA, Huber I, et al. Thromboembolism and bleeding tendency in congenital factor XII deficiency - a study on 74 subjects from 14 swiss families. Thromb Haemost 1991; 965: 117-21.
27. Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fisher M. The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost 1992; 68: 285-90.
28. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997; 90: 3819-43.
29. Sugi T, Makino T. Plasma contact system, kallikrein-kinin system and antiphospholipid-protein antibodies in thrombosis and pregnancy. J Reprod Immunol 2000; 47: 169-84.
30. Mannhalter C, Fisher M, Hopmeier P, Deutch E. Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. Fibrinolysis 1987; 1: 259.
31. von Kanel R, Wuillemin WA, Furlan M, Lammle B. Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coagul Fibrinolysis 1992; 3: 555.
32. Sugi T, McIntyre JA. Autoantibodies to kininogen-phosphatidylethanolamine complexes augment thrombin-induced platelet aggregation. Thromb Res 1996; 84: 97-10.
33. Meloni FJ, Schmaier AH. Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation. J Biol Chem 1991; 266: 6786-94.
34. Schmaier AH, Smith PM, Purdon AD, White JG, Colman RW. High molecular weight kininogen. Localization in the unstimulated and activated platelet and activation by a platelet calpain(s). Blood 1986; 67: 119-30.
35. Gustafson EJ, Schutsky D, Knight LC, Schmaier AH. High molecular weight kininogen binds to unstimulated platelets. J Clin Invest 1986; 78: 310-8.
36. Jiang YP, Muller-Esterl W, Schmaier AH. Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets. J Biol Chem 1992; 267: 3712-7.
37. Kunapuli SP, Bradford HN, Jameson BA, et al. Thrombin-induced platelet aggregation is inhibited by the heptapeptide Leu271-Ala277 domain 3 in the heavy chain of high molecular weight kininogen. J Biol Chem 1996; 271: 11228.
38. Sugi T, McIntyre JA. Certain autoantibodies to phosphatidylethanolamine (aPE) recognize factor XI and prekallikrein independently or in addition to the kininogens. J Autoimmunity 2001; 17: 207-4.
39. Bode W, Engh R, Musil D, et al. The 2.0 Å X-ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. EMBO J 1988; 7: 2593-9.
40. Miatello RM, Lama M, Gonzalez S, Damiani T, Nolly H. Biochemical evidence for a kallikrein-like activity in rat reproductive tissue. Hypertension 1994; 23 (Suppl. 1): 193-7.
41. Weerasinghe KM, Gadsby JE. The presence of glandular kallikrein in rabbit fetal placental conditioned medium. Endocrinology 1992; 131: 1777-81.
42. Mutoh S, Kobayashi M, Hirata J, et al. Studies on blood coagulationfibrinolysis system regarding kallikrein-kinin system in the uteroplacental circulation during normal pregnancy, labor and puerperium. Agents Actions 1992; 38: 320-9.
43. Hermann A, Buchinger P, Somlev B, Rehbock J. High and low molecular weight kininogen and plasma prekallikrein/plasma kallikrein in villous capillaries of human term placenta. Placenta 1996; 17: 223-30.
44. Brown NJ, Nadeau JH, Vaughan DE. Selective stimulation of tissue type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997; 77: 522.
45. Hossain AM, Whitman GF, Khan I. Kininogen present in rat reproductive tissues is apparently synthesized by the liver, not by the reproductive system. Am J Obstet Gynecol 1995; 173: 830-4.
46. Brann DW, Greenbaum L, Mahesh VB, Gao X. Changes in kininogens and kallikrein in the plasma, brain, and uterus during pregnancy in the rat. Endocrinology 1995; 136: 46-51.
47. Adam A, Damas J, Galay G, Bourdon V. Quantification of rat Tkininogen using immunological methods. Biochem Pharmacol 1989; 38: 1569-75.
48. Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985; 313: 1322-6.
49. Petri M. Pathogenesis and treatment of the antiphospholipid antibody syndrome. Adv Rheumatol 1997; 81: 151-77.
50. Nore M. This was just number fifty with no text. Adv Rheumatol 1997; 8: 15-77.
51. Katano K, Aoki K, Sasa H, Ogasawara M, Matsuura E, Yagami Y. b2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod 1996; 11: 509-12.
52. Herwald H, Hasan AAK, Godovac-Zimmermann J, Schmaier AH, Muller-Esterl W. Identification of an endothelial cell binding site on kininogen domain 3. J Biol Chem 1995; 270: 14634-42.